This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
The molecular diagnostic company reported last month second-quarter earnings of $28.3 million, or 33 cents a share. Earnings increased 17% from the previous year.
Myriad Genetics' estimated P/E for next year is 16.7. The average forward P/E among biotechnology companies is 44.38.
United Therapeutics(UTHR) had a forward P/E of 7.81.
Of Myriad Genetics' Prolaris presentation at the ASCO-GU conference Thursday, Oppenheimer analysts wrote in a report Thursday, "MYGN is ramping up its sales force, doubling the size to 20, as mgmt believes prostate cancer to represent a large opportunity with an annual incidence of 241k pre-prostatectomy patients and a prevalence of 1M post-prostatectomy patients. Initial launch is planned in the pre-prostatectomy indication, with payor talks ongoing."
Eleven of the 20 analysts who cover the company rated it a buy. Nine considered it a hold.
TheStreet Ratings gives Myriad a B- grade with a
$27.69 price target. The stock closed Thursday at $23.66 and has increased 15% year to date.
>>To see these stocks in action, visit the
4 Upgraded, Undervalued Stocks portfolio on Stockpickr.
The following companies also received upgrades to buy from
TheStreet Ratings Friday.
Hyatt Hotels:(H) B- grade from TheStreet Ratings and a $49.61 price target. The stock closed Thursday at $42.84.
Intersil:(ISIL) B grade from TheStreet Ratings and a $13.48 price target. The stock closed Thursday at $11.02.